ReviewCell communication and signaling : CCS2026
Circadian clock and its potential as a therapy for ischemic heart disease.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
According to an epidemiological survey, myocardial infarction, ischemia-reperfusion injury, and aortic rupture usually occur in the morning and summer and are characterized by more severe symptoms and poorer prognosis. The occurrence, development, treatment difficulties, and poor prognosis of ischemic heart disease are closely related to circadian rhythm disorders and the abnormal transcription of circadian clock genes. Normal circadian rhythms regulate neurohumoral regulation and energy metabolism, thereby playing a protective or modulatory role in ischemic heart disease (IHD). HIF1α links the IHD and circadian signaling pathways through the hypoxia response element (HRE) and Per-Arnt-Sim (PAS) domains in gene promoters and enhancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.